http://link.springer.com/article/10.1007/BF03324139
- Teresa Cenacchi
- , T. Bertoldin
- , C. Farina
- , M. G. Fiori
- , G. Crepaldi
- , C. F. Azzini
- , R. Girardello
- , B. Bagozzi
- , R. Garuti
- and 60 more
Abstract
This double- blind study
assesses the therapeutic efficacy and the safety of oral treatment with
phosphatidylserine (BC- PS) vs placebo (300 mg/day for 6 months) in a
group of geriatric patients with cognitive impairment. A total of 494
elderly patients (age between 65 and 93 years), with moderate to severe
cognitive decline, according to the Mini Mental State Examination and
Global DeteriorationScale, were recruited in 23 Geriatric or General
Medicine Units in Northeastern Italy. Sixty- nine patients dropped out
within the 6- month trial period. Patients were examined just before
starting therapy, and 3 and 6 months thereafter. The efficacy of
treatment compared to placebo was measured on the basis of changes
occurring in behavior and cognitive performance using the Plutchik
Geriatric Rating Scale and the Buschke Selective Reminding Test.
Statistically significant improvements in the phosphatidylserine-
treated group compared to placebo were observed both in terms of
behavioral and cognitive parameters. In addition, clinical evaluation
and laboratory tests demonstrated that BC- PS was well tolerated. These
results are clinically important since the patients were representative
of the geriatric population commonly met in clinical practice. (Aging
Clin. Exp. Res. 5: 123- 133, 1993).
